Conference on Drug Formulation Technologies (Addressing compatibi)

Venue: BSG Conference Centre

Location: London, United Kingdom, India

Event Date/Time: Nov 04, 2008 End Date/Time: Nov 05, 2008
Report as Spam


Conference on Drug Formulation Technologies
Addressing compatibility issues between formulation and drug-delivery systems for specified final dosage forms
Held at 4th – 5th November 2008 , BSG Conference Centre, London, UK

Key Speakers

Dr Sven Stegemann, Director Global Pharmaceutical Business Development, Capsugel
Dr Richard White, Manager Toxicology and Pharmacology, OphthalmoPharma
Dr Cornelus van Nostrum, Associate Professor, Department of Pharmaceutics, Utrecht Institute of Pharmaceutical Sciences
Professor Andreas Bernkop-Schnuerch, Chief Scientific Officer, University of Innsbruck
Dr Peter Scholes, Vice President Pharmaceutical Sciences, Pharmaceutical Profiles
Dr Woei Ping Cheng, Lecturer in Pharmaceutics, School of Pharmacy and Life Sciences, The Robert Gordon University
Professor Amnon Hoffman, Chairman, Dept. of Pharmaceutics, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem
Professor Alfred Fahr, Chair of Pharmaceutics, Fredrich Schiller University of Jena
Randy Mellaerts, Centre for Surface Science Catalysis, University of Leuven
Professor Howar
d Stevens, Assistant Head of Institute and Professor of Drug Delivery, University of Strathclyde

Conference Introduction

Drug Formulation Technologies 4th – 5th November 2008 , London, UK

Dear Colleague,

A great deal of publicity has emerged with respect to drug-delivery systems in relation to innovation in the fi eld of formulation. These technologies have ultimately
been designed to improve the effi cacy of chemical entities and deliver the desired therapeutic effect of drugs, both novel and established, which are available in
today’s healthcare and affi liated markets.

The need to address formulation issues occurs in a number of industries from: agriculture - with respect to fertilisers and pesticides; to the development of pharmaceuticals as found in biology and medicine; as well as in the chemicals industry for the manufacture of high performance paints and pigments. With advancements in technology, formulations being developed through nanoscience (for example) are enabling technology transfer to work across these industrial
sectors, which is creating a stimulating environment for innovation.

Visiongain’s Drug Formulation Technologies 2008 conference, will ultimately create the appropriate environment for an exchange of key concepts and ideas with respect to developments in formulation technologies all occuring across drug-delivery platforms in the healthcare industry.

The predominant focus of this conference will be in advancements being made in the field of formulation in terms of drug development research in areas including
dissolution, solubilisation, and optimised stability, as well as fi nal dosage forms ready to be used in combination with novel or improved drug-delivery systems.

Reasons to register today
• To gain a current and focused overview of formulation technologies in the drug industry
• To assess and forecast the future of innovation in the drug formulations affiliated industries
• To understand the issues faced in aligning drug formulation with drug-delivery
• To develop an up-to-date understanding of the product management framework created by Speciality Pharma business-models
• To explore integrated business-network solutions in order to troubleshoot Pharma pipeline projects associated with formulation
• To determine the viability of current research into new and emerging areas of formulation technology in relation to nanoscience
• To create a suitable networking environment for the appropriate senior business developers and scientific leaders in the industry

I look forward to meeting you at this conference,
Best regards,

Toby Roy
Conference Producer

Who will attend?

CEOs, Directors, Senior Business Developers, Senior and Chief Scientific Officers, Formulation and Pre-formulation Experts and

Specialists, Drug-delivery teams, and Consultants from:

• Pharmaceutical and Biotechnology companies
• The Speciality Pharma industry
• Drug-delivery technology companies
• The Generic-based Pharma & Biotech industries
• Contract Research Organisations
• Regulatory Bodies
• Outsourcing-based organisations: Manufacturing and Equipment based
• Investment and Finance-based companies
• Marketing-based organisations

Day 1 (Drug Formulation Technologies Tuesday 4th November 2008)
Drug Formulation Technologies Tuesday 4th November 2008

09:30 Registration and refreshments

10:00 Opening address from the chair

Dr Sven Stegemann
Director Global Pharmaceutical Business Development

10:10 A novel delivery system aimed to enhanced the oral bioavailability of lipophilic P-gp substrate drugs
10:50 In vitro In vivo Correlation (IVIVC): Application to formulation design, bioequivalence, & dissolution specifications

Fiona McInnes
University of Strathclyde*

11:30 Morning refreshments
11:50 Ordered mesoporous silica as a carrier for poorly
water soluble drugs

• Dissolution enhancement of poorly water soluble drugs
• Tailor made design of silica based carrier materials
• Supersaturation of itraconazole in biorelevant media
• Biopharmaceutical evaluation of ordered mesoporous silica

Randy Mellaerts
Centre for Surface Science Catalysis
University of Leuven

12:30 Liposomal formulations for poorly soluble drugs
• Which pre-requisites has a drug to have to be successfully formulated in liposomes?
• Biophysics as essential methodology for identifying compatibility problems
• Successful formulations on the market - case study: photosensitiser formulation in liposomes – unexpected advantages.

Professor Alfred Fahr
Chair of Pharmaceutics
Fredrich Schiller University of Jena

13:10 Networking lunch

14:30 Design of transdermal gels for systemic drug delivery

• Advantages of transdermal gels compared to patches
• Drug selection criteria for suitability to transdermal drug delivery
• General formulation composition and attributes
• In vitro testing of formulation prototypes
• Prediction of in vivo performance based on in vitro testing
• Formulation stability issues

Head of Preclinical Development
Antares Pharma

15:10 The use of amphiphilic polymers as emerging delivery systems for small drug molecules and macromolecules

• Overview of amphiphilic polymers vs. conventional surfactants
• The use of these systems in addressing the challenges in hydrophobic drug solubilisation and protein delivery
• Evaluate the advantages and limitations of the delivery systems
• Future direction of the delivery systems, looking at preclinical and clinical studies

Dr Woei Ping Cheng
Lecturer in Pharmaceutics, School of Pharmacy and Life Sciences
The Robert Gordon University

15:50 Afternoon refreshments

16:10 Application of solid dispersion and nanoparticulate formulation technologies for poorly soluble drug candidates

• Identification of solid dispersions and nanoparticulate formulations as technologies to overcome poor solubility and bioavailability issues
• The importance of elucidating the background to these approaches with respect to the increasing numbers of products appearing in the market
• Discussion of former hurdles and current improvements of understanding, selecting, and applying technologies successfully to new molecules
• Case study discussion illustrating a solvent based process for making solid dispersions, illustrating current achievements in this field

16:30 Drug Delivery and individualised therapy: Towards flexibility in development and manufacturing

• Overview of multiparticulate drug delivery systems for immediate and modified release
• Introduction into lipid drug delivery systems to enhance bioavailability
• Understand the improved PK profile of multiparticulate and liquid drug delivery systems
• Select the most flexible dosage form to cope with the increasing dose ranges

Dr Sven Stegemann
Director Global Pharmaceutical Business Development

17:10 Closing remarks from the chair

17:15 Networking drinks reception
Take your discussions further and build new relationships in a relaxed and informal setting.

Day 2 (Drug Formulation Technologies Tuesday 4th November 2008)

09:30 Registration and refreshments

10:00 Opening address from the chair
Dr. Cornelus van Nostrum
Associate Professor, Department of Pharmaceutics
Utrecht Institute of Pharmaceutical Sciences

10:10 Understanding the performance of drug delivery
systems in man
• Use of ‘old’ excipients to develop novel drug formulation strategies
• Case studies in oral and nasal drug delivery
• Using gamma scintigraphy to visualise in-vivo performance of formulations
• Quantification of in-vivo behaviour of pharmaceutical formulations
Professor Howard Stevens
Assistant Head of Institute and Professor of Drug Delivery
University of Strathclyde

10:50 Multifunctional polymeric excipients: teaching
(old) drugs new tricks
• Types of polymeric excipients
• Mucoadhesive, in-situ gelling, release controlling, permeation
enhancing and efflux pump inhibiting properties
• Proof of principle studies
• Safety aspects
Prof. Dr. Andreas Bernkop-Schnuerch
Chief Scientific Officer
University of Innsbruck

11:30 Morning refreshments

11:50 Formulation strategies for use in injectable or
inhalation sevices
• Analysis of attempts at delivery via the oral route – the prospects for
biopharmaceuticals in upcoming years
• The surge in formulations for antibodies:promising routes of delivery
• Fresh approaches to protein formulation and delivery

12:30 Modified Release oral formulations: Using human
regional bioavailability data to ensure success and
maximise value

• Identifying the critical drivers for MR formulation technology selection
• Confirming the potential oral developability of the candidate molecule
versus the proposed target product profile
• Selecting the most appropriate drug delivery and/or solubilisation
technologies to achieve the desired pharmacokinetic (PK) delivery profile
• Using regional bioavailability data to generating a proactive “MR
formulation road-map” to expedite initiation of PoX studies
• Opportunities for enhanced formulation IP protection by strengthening
the inventive step

Dr Peter Scholes
VP Pharmaceutical Sciences
Pharmaceutical Profiles Ltd

13:10 Networking lunch

14:30 Challenges and solutions at the manufacturing stage of the drug delivery process

James Drinkwater
Process Director Bioquell UK, Vice Chairman
Pharmaceutical and Healthcare Sciences Society*

15:10 Systems for regio-selective drug delivery in the gastrointestinal tract

• Absorption windows along the GI tract
• Controlled Release - Gastroretentive Dosage Forms (CR-GRDF)
• Drugs that would benefit from CR-GRDF
• Lipid vehicles for lipophilic drugs - Intelligent selection
• Lymphatic transport

Prof. Amnon Hoffman

Chairman, Dept. of Pharmaceutics, School of Pharmacy, Faculty of Medicine

The Hebrew University of Jerusalem

15:50 Afternoon refreshments

16:10 Mono-substituted cyclodextrins in ocular reformulation

• Beta Monosubstituted Cyclodextrins are complex, water-soluble glucose oligomers with a hydrophobic core.
• The core hydrophobicity makes them drug delivery vehicles for insoluble or poorly water-soluble compounds.
• Capture candidates include steroids, peptides, natural compounds and a host of small to large molecular weight drug candidates.
• Once diluted in a complex fluid like tears, the on-off equilibrium favours slow release increasing the half-life and favouring better ocular penetration

Dr Richard White
Manager Toxicology and Pharmacology

16:50 Design of polymeric micelles as true carriers for the controlled delivery of hydrophobic drugs

• Use of thermosensitive polymers enables convenient and continuous formulation process
• Transient stability of micelles provides delayed drug release
• Systemic drug circulation time and biodistribution can be improved by crosslinking of the micelles
• Aiming for chemotherapy and photodynamic therapy of cancer
• Prospects for oral delivery will be discussed

Dr. Cornelus van Nostrum, Ph.D.
Associate professor, Department of Pharmaceutics
Utrecht Institute of Pharmaceutical Sciences

17:30 Chair’s closing remarks and end of conference

For more information kindly visit:


BSG Conference Centre, London, UK
United Kingdom